|
|
|
|
CBio Secures Another Clinical Trial Milestone
-- Milestone triggers $1 million payment from Novo Nordisk A/S -- Payment follows earlier milestone approvals for clinical trial sites in Central and Eastern Europe BRISBANE, Australia, March 11 /PRNewswire/ -- Australian drug development company...
|
|
|
West Coast Clinical Trials Opens Second Facility In Costa Mesa, California
/24-7PressRelease/ -- The new unit will enable WCCT to house additional clinical research participants, and expand their base of operations.Tom Pillsworth, Vice President of Business Development has stated, 'The new unit has been designed specifically...
|
|
|
FDA Allows IND for Bio-Path Holdings Liposomal Grb-2
Company to Commence Phase I Clinical Trial of Its Cancer Drug Candidate to Treat CML, AML, ALL & MDS HOUSTON(BUSINESS WIRE) Bio-Path Holdings, Inc.(OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in...
|
|
|
Age Related Macular Degeneration Clinical Trial: Reports summarize age related macular degeneration clinical trial study results from United BioSource Corporation
Age Related Macular Degeneration Clinical Trial Data detailed in 'Reliability and validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration' have been presented.In this recently...
|
|
|
News and FDA Updates for Stem Cell Assurance (OTC:SCLZ), Synta (NASDAQ:SNTA)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical ...
|
|
|
News and FDA Updates for Clinical Data (NASDAQ:CLDA), Enzo (NYSE:ENZ), GTC (NASDAQ:GTCB)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical ...
|
|
|
BiomedReports: News and FDA Updates for Stem Cell Assurance (OTC:SCLZ), Synta (NASDAQ:SNTA)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical ...
|
|
|
AngioScore Announces Favorable Results from the MASCOT Trial
AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced today favorable clinical trial results from the MASCOT Trial, an important study evaluating the AngioSculpt PTA Scoring...
|
|
|
AngioScore Announces Favorable Results from the MASCOT Trial
Companies mentioned in this article: AngioScore, Inc.FREMONT, Calif. -- (BUSINESS WIRE) -- AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced today favorable clinical trial...
|
|
|
Allon's Phase 1 Trial Broadens Davunetide's Intranasal Safety and Dose Range
Allon Therapeutics announced that a Phase 1 clinical trial of its lead neuroprotective drug, davunetide, which began patient enrolment January 28, 2010, has been completed VANCOUVER, BRITISH COLUMBIA, CANADA | March 11, 2010 | Allon Therapeutics Inc...
|
|
|
FDA Allows IND for Bio-Path Holdings' Liposomal Grb-2
HOUSTON - (BUSINESS WIRE) - Bio-Path Holdings, Inc.(OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration (FDA) has allowed an IND ...
|
|
|
CBio Secures Another Clinical Trial Milestone
Milestone triggers $1 million payment from Novo Nordisk A/S Payment follows earlier milestone approvals for clinical trial sites in Central and Eastern Europe Brisbane, Australia /PRNewswire/ -- Australian drug development company CBio Limited (ASX:...
|
|
|
Increased Customer Retention & More Accurate Trial Results in the Global Clinical Trials Industry
ESTON, FLMARKETWIRE When Steve Levenson learned that a leading global clinical trials company was losing clients and repeating costly clinical trials because the international phone numbers assigned to its customers were flawed, he knew...
|
|
|
CBio Secures Another Clinical Trial Milestone
Australian drug development company CBio Limited (ASX: CBZ) announced the achievement of a clinical trial milestone under its option agreement with global pharmaceutical leader Novo Nordisk A/S.The agreement relates to the development of XToll,...
|
|
|
CBio Secures Another Clinical Trial Milestone
BRISBANE, Australia, March 11 /PRNewswire/ -- Australian drug development company CBio Limited (ASX: CBZ.AX) today announced the achievement of a clinical trial milestone under its option agreement with global pharmaceutical leader Novo Nordisk A/S....
|
|
|
Takara Bio to Enter into a Collaborative Research Agreement with University of Pennsylvania, Aiming for a Future Clinical Trial of HIV Gene Therapy
(JCN Newswire via COMTEX) ----Takara Bio Inc.announced today that it has executed a collaborative research agreement with University of Pennsylvania on March 11, 2010 to support an HIV gene therapy clinical trial in the United States. Under...
|
|
|
Takara Bio to Enter into a Collaborative Research Agreement with University of Pennsylvania, Aiming for a Future Clinical Trial of HIV Gene Therapy
(JCN Newswire via COMTEX) ----Takara Bio Inc.announced today that it has executed a collaborative research agreement with University of Pennsylvania on March 11, 2010 to support an HIV gene therapy clinical trial in the United States. Under...
|
|
|
Takara Bio to Enter into a Collaborative Research Agreement with University of Pennsylvania, Aiming for a Future Clinical Trial of HIV Gene Therapy
- (JCN Newswire) - Takara Bio Inc.announced today that it has executed a collaborative research agreement with University of Pennsylvania on March 11, 2010 to support an HIV gene therapy clinical trial in the United States. Under this agreement...
|
|
|
Takara Bio to Enter into a Collaborative Research Agreement with University of Pennsylvania, Aiming for a Future Clinical Trial of HIV Gene Therapy
- (JCN Newswire) - Takara Bio Inc.announced today that it has executed a collaborative research agreement with University of Pennsylvania on March 11, 2010 to support an HIV gene therapy clinical trial in the United States. Under this agreement...
|
|
|
Takara Bio to Enter into a Collaborative Research Agreement with University of Pennsylvania, Aiming for a Future Clinical Trial of HIV Gene Therapy
- (JCN Newswire) - Takara Bio Inc.announced today that it has executed a collaborative research agreement with University of Pennsylvania on March 11, 2010 to support an HIV gene therapy clinical trial in the United States. Under this agreement...
|
|
|
FDA Allows IND for Bio-Path Holdings?? Liposomal Grb-2
3/12/10 - FDA Allows IND for Bio-Path Holdings Liposomal Grb-2 Company to Commence Phase I Clinical Trial of Its Cancer Drug Candidate to Treat CML, AML, ALL & MDS HOUSTON(BUSINESS WIRE) Bio-Path Holdings, Inc.(OTCBB: BPTH), a publicly traded...
|
|
|
CBio secures clinical trial milestone under option agreement with Novo Nordisk
(Datamonitor via COMTEX) Australian drug development company CBio has achieved a clinical trial milestone under its option agreement with Denmark-based pharmaceutical company Novo Nordisk.The agreement relates to the development of XToll, the...
|
|
|
CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk
Australian drug development company CBio Limited (ASX: CBZ) today announced the achievement of a clinical trial milestone under its option agreement with global pharmaceutical leader Novo Nordisk A/S.The agreement relates to the development of...
|
|
|
CBio secures clinical trial milestone under option agreement with Novo Nordisk
Australian drug development company CBio has achieved a clinical trial milestone under its option agreement with Denmark-based pharmaceutical company Novo Nordisk.The agreement relates to the development of XToll, the potential new-generation...
|
|
|
Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
Amsterdam Molecular Therapeutics announced that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease.Amsterdam, The...
|
